A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of JNJ-77242113 for the Treatment of Biologic-naïve Participants with Active Psoriatic Arthritis

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-509239-19-00

Acronym

77242113PSA3001

Enrollment

337

Registered

2025-04-02

Start date

2025-04-03

Completion date

Unknown

Last updated

2025-10-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Active Psoriatic Arthritis

Brief summary

The primary endpoint is the American College of Rheumatology (ACR) 20 response at Week 16

Interventions

DRUGSTELARA 90 mg solution for injection in pre-filled syringe

DRUGJNJ-77242113

DRUGSolution for injection in pre-filled syringe without Ustekinumab 90

DRUGJNJ-77242113-AAC Placebo tablet

DRUGSTELARA 45 mg solution for injection

DRUGSolution for injection in pre-filled syringe without Ustekinumab 45

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
The primary endpoint is the American College of Rheumatology (ACR) 20 response at Week 16	—

Countries

Bulgaria, Czechia, Denmark, Germany, Hungary, Poland, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026

​​A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of JNJ-77242113 for the Treatment of Biologic-naïve Participants with Active Psoriatic Arthritis​